Protective effects of gonadotropin releasing hormone agonist on ovarian function in patients with early stage cervical cancer undergoing ovarian preservation
LI Hui-rong;ZHANG Tong-mei;Department of Gynecology, Baoji Maternal and Child Health Hospital;
Objective To investigate the protective effect of gonadotropin releasing hormone(GnRH) agonist on ovarian function in patients with early stage cervical cancer undergoing ovarian preservation. Methods A total of 80 patients with early cervical cancer in Baoji Maternal and Child Health Hospital from January 2014 to March 2016 were enrolled. Using random number table method, the patients were divided into control group and observation group, with 40 cases in each groups. The two groups were treated with radical operation with ovarian preservation, and the patients received 4 courses of PT program adjuvant chemotherapy after surgery. At the same time, the observation group was treated with GnRH agonist. The levels of basal follicle stimulating hormone(bFSH), serum anti-Mullerian hormone(AMH), basal estrogen(bE2) and basal antral follicle count(bAFC) were compared between the two groups before and after chemotherapy. Results There was no significant difference in bFSH and bE2 levels between the two groups before chemotherapy.After chemotherapy, the levels of bFSH and bE2 in the observation group were significantly lower than those in the control group:(6.72±2.58) IU/L vs(22.13±6.36) IU/L,(45.87±12.24) pg/mL vs(58.75±17.03) pg/mL, P0.05. There was no significant difference in AMH level and bAFC between the two groups before chemotherapy. After chemotherapy, the AMH level and bAFC in the observation group were significantly higher than those in the control group:(2.17±1.47) μg/L vs(0.89±0.59) μg/L,(11.93±3.23) vs(3.75±3.01), P0.05. Conclusion GnRH agonists can effectively protect ovarian reserve function in early cervical cancer patients undergoing radical operation with ovaries reserved. It is worthy of clinical application.
【CateGory Index】： R737.33